Across TCGA pan-cancer cohorts, RPL39 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RPL39 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RPL39 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPL39 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where RPL39 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	III,IV	0.337	0.986	.004	9	view →
LUAD	DFS	Quartile	All	0.782	0.404	.026	8	view →
CCRCC	OS	Median	IV	0.451	1.000	.016	7	view →
HNSC	DFS	Tertile	III,IV	1.000	0.367	.049	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RPL39 tumor-vs-normal RNA expression · all RPL39 data types